Management of Persistent Joint Pain with Elevated CRP

Diagnostic Approach

The combination of persistent joint pain and elevated CRP strongly suggests active inflammatory arthritis requiring urgent evaluation, and treatment should not be delayed waiting for complete serologic workup, as seronegative inflammatory arthritis accounts for 20-30% of cases and has similar prognosis to seropositive disease 1, 2
The American College of Rheumatology recommends starting methotrexate 15 mg weekly as first-line disease-modifying therapy immediately, combined with short-term low-dose prednisone (10-20 mg daily) as bridge therapy, while completing diagnostic workup to confirm inflammatory arthritis 1

Complete blood count with differential should be ordered to assess for cytopenias before starting treatment, with a strength of evidence level of high 1
Comprehensive metabolic panel including liver and renal function, as required for DMARD monitoring, should be performed, with a strength of evidence level of high 1, 2
Hepatitis B, Hepatitis C, and tuberculosis screening should be done before any biologic therapy, with a strength of evidence level of high 1

Bilateral hand, wrist, and foot X-rays at baseline are recommended to assess for erosions, which predict RA diagnosis and disease persistence, with a strength of evidence level of moderate 1
Ultrasound with Power Doppler or MRI is recommended if clinical examination shows no definite synovitis but suspicion remains high, with a strength of evidence level of moderate 1

Methotrexate 15 mg weekly is the anchor drug and should be started immediately, with a plan to escalate to 20-25 mg weekly if inadequate response after 4-6 weeks, with a strength of evidence level of high 1
Short-term low-dose prednisone (10-20 mg daily) is recommended as bridge therapy while awaiting DMARD effect, with a strength of evidence level of moderate 1
Naproxen 500 mg twice daily is an alternative NSAID with established efficacy, and should always be combined with proton pump inhibitor for gastroprotection, with a strength of evidence level of moderate 3, 4

Disease activity should be reassessed every 4-6 weeks using SDAI or CDAI, with a strength of evidence level of high 1
CRP and ESR should be repeated at each visit to monitor inflammatory activity, with a strength of evidence level of moderate 1
Hand, wrist, and foot X-rays should be repeated at 6 and 12 months to monitor radiographic progression, with a strength of evidence level of moderate 1

Referral to occupational therapy is recommended for joint protection education, assistive devices, and splinting, with a strength of evidence level of moderate 1
Dynamic exercise program incorporating aerobic exercise and progressive resistance training is recommended, with a strength of evidence level of moderate 1
Tobacco cessation counseling is recommended, as smoking is a modifiable predictor of adverse outcomes, with a strength of evidence level of high 1
Patient education about disease nature and management is recommended, with a strength of evidence level of moderate 5

Referral to rheumatology within 6 weeks of symptom onset is recommended if not already done, with a strength of evidence level of high 1, 2